ORIC Stock Sees Biggest Intraday Slump In Over Four Years – Analyst Says Selloff 'Appears Exaggerated’

• Jones Research maintained a ‘Buy’ rating on the stock with a $25 price target, according to The Fly.
• Wedbush Securities lowered its price target to $17 from $20 but maintained an ‘Outperform’ rating.
• Cantor Fitzgerald said Rinzimetostat’s efficacy appears comparable to competitor Mevrometostat from Pfizer

Shares of Oric Pharmaceuticals (ORIC) plunged 28% on Wednesday as investors reacted to tolerability concerns tied to a higher dose of its prostate cancer drug, even as analysts said the sharp sell-off appears exaggerated.

ORIC shares recorded their biggest intraday slump in more than four years.

Oric Selects 400 MG Dose Of Rinzimetostat

On Tuesday, Oric announced it selected a lower 400 mg dose of its investigational drug Rinzimetostat. In the Phase 1 trial involving patients with metastatic castration-resistant prostate cancer, the 600 mg dose showed a higher rate of side effects, dose interruptions, and discontinuations when combined with darolutamide.

By contrast, the 400 mg dose demonstrated a more manageable safety profile, with mostly mild side effects and only limited severe (Grade 3) events. The company now plans to move forward with the lower dose in a global Phase 3 trial in the first half of 2026.

Analysts Say Selloff is Exaggerated

Despite the sharp selloff, analysts suggest the reaction may be overdone. Jones Research noted that the data appears broadly in line with Pfizer’s competing drug Mevrometostat, while potentially offering a better safety profile, according to The Fly.

The firm said the selloff ‘appears exaggerated,” pointing out that Oric’s data is still early, with only about five months of follow-up compared to nine to 10 months for Pfizer’s results. Jones  Research maintained a ‘Buy’ rating on the stock with a $25 price target.

Other firms, including Cantor Fitzgerald and Wedbush, highlighted that efficacy remains comparable. “Efficacy appears comparable to competitor Mevrometostat from Pfizer, with Rinzi showing a potentially better safety profile,” Cantor said. It has an ‘Overweight’ rating on Oric shares.

Wedbush Says Results broadly In Line With Pfizer’s Drug

Meanwhile, David Nierengarten of Wedbush Securities lowered his price target to $17 from $20 while maintaining an ‘Outperform’ rating. The analyst said Oric’s Phase 1 prostate cancer results are broadly in line with Pfizer’s, even though Oric tested its drug in a sicker patient group.

He added that while greater efficacy differences are ideal, better tolerability is important, especially for older patients on long-term treatment, and could influence doctors’ choices if both drugs are similarly effective.

Despite the sharp selloff, retail sentiment turned ‘extremely bullish’ from ‘neutral’ a day earlier.

One user said the stock has "really good upside potential"

The stock has gained more than 10% so far in 2026.

Read also: ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses

For updates and corrections, email newsroom[at]stocktwits[dot]com.